Cargando…

Comparative Efficacy of Combined Radiotherapy, Systemic Therapy, and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-Analysis and Systematic Review

Background: Recent randomized clinical trials have examined the efficacy of different combinations of systemic and local treatment approaches for metastatic hormone-sensitive prostate cancer (mHSPC). We compared the efficacy of these combined regimens in order to identify the optimal therapy for spe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yuhan, Gui, Huiming, Wang, Juan, Tian, Junqiang, Wang, Hanzhang, Liang, Chaozhao, Hao, Zongyao, Rodriguez, Ronald, Wang, Zhiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606969/ https://www.ncbi.nlm.nih.gov/pubmed/33194648 http://dx.doi.org/10.3389/fonc.2020.567616

Ejemplares similares

Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Is there still a role for bilateral orchidectomy in androgen-deprivation therapy for metastatic prostate cancer?
por: Atta, Mohamed Adel, et al.
Publicado: (2019)

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy
por: Graff, Julie N., et al.
Publicado: (2020)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Elevated testosterone on immunoassay in a patient with metastatic prostate cancer following androgen deprivation therapy and bilateral orchiectomy
por: Sarkar, Arjun, et al.
Publicado: (2021)

Androgen Deprivation Therapy Combined With Particle Therapy for Prostate Cancer: A Systematic Review
por: Petersen, Stine Elleberg, et al.
Publicado: (2021)

WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?
por: Omrčen, Tomislav
Publicado: (2019)

Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy
por: Carrasquilla, Michael, et al.
Publicado: (2021)

Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial
por: Yang, Dingyuan, et al.
Publicado: (2023)

Androgen-Deprivation Therapy and Cardiovascular Disease Risk – The Role of Exercise in Prostate Cancer Treatment
por: Wall, Bradley
Publicado: (2016)

Testicular recurrence of oligometastatic prostatic adenocarcinoma after 22 years of androgen deprivation therapy
por: Fortier, Alexa, et al.
Publicado: (2022)

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
por: Røe, Kathrine, et al.
Publicado: (2012)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
por: Amit, Uri, et al.
Publicado: (2019)

Molecular classifications of prostate cancer: basis for individualized risk stratification and precision therapy
por: Ge, Qintao, et al.
Publicado: (2023)

Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
por: Kashiwagi, Eiji, et al.
Publicado: (2020)

Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancer
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?
por: Eom, Keun-Yong, et al.
Publicado: (2014)

Neurocognitive effects of androgen deprivation therapy and new hormonal agents in a sample of patients with metastatic prostate cancer
por: Ihrig, Andreas, et al.
Publicado: (2023)

Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their combination
por: Lee, Sung Uk, et al.
Publicado: (2017)

Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
por: Hu, Linjun, et al.
Publicado: (2020)

First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study
por: Viscuse, Paul V., et al.
Publicado: (2019)

Cryosurgery Versus Primary Androgen Deprivation Therapy for Locally Recurrent Prostate Cancer After Primary Radiotherapy: A Propensity-Matched Survival Analysis
por: Bauman, Glenn, et al.
Publicado: (2020)

Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
por: Park, Kwonoh, et al.
Publicado: (2023)

A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy
por: Liu, Qiuli, et al.
Publicado: (2018)

Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis
por: Matsumura, Naoki, et al.
Publicado: (2021)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
por: Wang, Yue, et al.
Publicado: (2017)

Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer’s Disease and Neurodegeneration: Old Drugs, New Concerns
por: Achard, Vérane, et al.
Publicado: (2021)

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
por: Mason, Malcolm D., et al.
Publicado: (2015)

Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone
por: Kanao, Kent, et al.
Publicado: (2022)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier
por: Etheridge, Tyler, et al.
Publicado: (2019)

Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis
por: Fiorica, Francesco, et al.
Publicado: (2022)

Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
por: Maiorano, B.A., et al.
Publicado: (2022)

Risk Factors of Biochemical Failure in Locally Advanced Carcinoma Prostate Treated With Definitive External Beam Radiotherapy and Androgen Deprivation Therapy: Experience From Tertiary Care Center in North India
por: Sidhu, Manjinder, et al.
Publicado: (2021)

Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer
por: Jung, Jaeyoon, et al.
Publicado: (2015)

What Is Your Choice for Androgen Deprivation Therapy in Metastatic Prostate Carcinoma: Surgical or Medical?
por: Salih Semiz, Huseyin, et al.
Publicado: (2022)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cbbpiivq0jo2os5lm9bbl6fr2n